Zobrazeno 1 - 10
of 154
pro vyhledávání: '"R Cheingsong"'
Autor:
Sj Machin, R. M. R. Barnes, G. C. Turner, M. J. Galloway, Mark Winter, Richard S. Tedder, B. A. Mcverry, P. Evans, K. Mccarthy, R. Cheingsong-Popov
Publikováno v:
British Journal of Haematology. 63:347-352
44% of 63 British patients with either haemophilia A or B were HTLV-III antibody positive (HTLV-VIII+). HTLV-III+ was more frequent in high factor VIII concentrate users and 75% of severely affected haemophilia A patients were HTLV-III+. All eight pa
Autor:
J Banatvala, Claudine Bruck, Gareth J. F. Jones, Simon Beddows, Frances M. Gotch, Abdel Babiker, Ann D. M. Rees, C. Van Hoecke, Anthea J Tilzey, Janet Darbyshire, Simon Lister, A Newberry, R Cheingsong, Jonathan Weber, A Carmichael, Sheena Mary Geraldine Mccormack, D. A. J. Tyrrell, J Kepple
Publikováno v:
Vaccine. 18:1166-1177
Thirty healthy HIV negative volunteers were randomised to receive 200 micrograms of rgp120W61D in either: 3D-MPL and QS21, with an oil and water emulsion (SBAS-2) (13); or 3D-MPL and QS21 (SBAS-1) (11); or alum (six). Immunizations were given at 0, 4
Autor:
Geoffrey M.W. Cook, Myra O. McClure, R A Weiss, R. Cheingsong-Popov, Denise Whitby, Clive Patience, N. J. Gooderham, J. N. Weber, A. Bradshaw, Donald S. Davies, Roger J. Keynes
Publikováno v:
Antiviral Chemistry and Chemotherapy. 2:149-156
Two sulphated polysaccharides, fucoidan (a derivative of seaweed) and the newly synthesised dextrin sulphate, were tested for their ability to inhibit human immunodeficiency virus (HIV) infection in vitro in comparison to dextran sulphate and azidoth
Publikováno v:
BMJ. 302:23-26
OBJECTIVE--To study the contribution of the humoral response to HIV-I at seroconversion to disease outcome after 84 months. DESIGN--A retrospective longitudinal study. SETTING--Two haemophilia centres in the United Kingdom. PATIENTS--88 Haemophiliac
Autor:
A Kovacs, Walid Heneine, Patrick S. Sullivan, R Respess, Jeffrey L. Jones, R Cheingsong, Susan E. Buskin, Marcia L. Kalish, A Saekhou, J H Turner
Publikováno v:
International journal of STDAIDS. 13(8)
Resistance testing for treatment-naïve, recently HIV-infected persons is not currently recommended; its clinical value will depend on the prevalence of resistance-associated mutations among recently infected persons. To estimate this prevalence, spe
Autor:
A, Bobkov, E, Kazennova, L, Selimova, N, Ladnaya, A, Kravchenko, B, Foley, I, Morrison, V, Pokrovsky, J, Weber, R, Cheingsong-Popov
Publikováno v:
AIDS research and human retroviruses. 14(17)
Autor:
R, Cheingsong-Popov, S, Osmanov, C P, Pau, G, Schochetman, F, Barin, H, Holmes, G, Francis, H, Ruppach, U, Dietrich, S, Lister, J, Weber
Publikováno v:
AIDS research and human retroviruses. 14(4)
V3 serotyping refers to a system based on binding of antibody in patient sera to V3-loop peptides derived from HIV-1 env genetic subtypes. The V3x serotype represents reactivity of serum from an HIV-1-infected patient (regardless of viral genetic sub
Autor:
A F, Bobkov, V V, Pokrovskiĭ, L M, Selimova, E V, Kazennova, N G, Karaseva, N N, Ladnaia, A V, Kravchenko, R, Cheingsong-Popov, J, Weber
Publikováno v:
Doklady Akademii nauk. 353(6)
Autor:
A, Bobkov, R, Cheingsong-Popov, M, Salminen, F, McCutchan, J, Louwagie, K, Ariyoshi, H, Whittle, J, Weber
Publikováno v:
AIDS research and human retroviruses. 12(2)
Publikováno v:
AIDS research and human retroviruses. 10(11)
We have investigated whether peptides representing the HIV-1 principal neutralization domain (V3) can be used as antigens in antibody-binding assays to predict the genotypes of the subjects' virus. Serum samples collected from HIV-1-infected subjects